Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Reaches access to an anonymised dataset of over 60 million patients. This results from both Sensyne's investment in virtual clinical development company Phesi in January 2021 and the progress being made by Sensyne and Phesi in building their respective data platforms. Between December 2020 and this past July, Phesi has grown its clinical research and clinical trial dataset from 13 million to 42 million patients. At the same time, Sensyne has grown its real world patient dataset from 6 million to over 18 million patients.
"Sixty million patients is an important milestone in our journey to create the world's best data resource for medical research. However, it is the quality and depth of the data across many disease areas and the combination of both clinical research data, clinical trials data and longitudinal real world data from electronic patient records, that makes the database such a powerful tool for research professionals in both the life sciences and healthcare sectors," said Chief Executive Paul Drayson PhD.
Current stock price: 152.38 pence, up 0.9% on Monday
Year-to-date change: up 35%
By Amrit Sahota; newsroom@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
